Aphton Announces Approval of its Application for Transfer to NASDAQ SmallCap Market.PHILADELPHIA -- Aphton Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :APHT APHT Advance Physical Test ) a biotechnology company focused on the development of immunotherapies for the treatment of cancer, today announced that commencing at the opening of business on July 25, 2005, the listing of its common stock will be transferred from The Nasdaq National Market to The Nasdaq SmallCap Market. The Company's common stock will continue to trade under the symbol APHT on the Nasdaq SmallCap Market. There will be no change in the way Aphton shares are traded as a result of the listing transfer, and the transfer will not have an effect on shareholders' ability to purchase and sell Aphton's common stock. Aphton's stock symbol remains APHT. About Aphton Aphton Corporation, headquartered in Philadelphia, Pennsylvania is a clinical stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. Aphton's products seek to empower the boy's own immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. to fight disease. Through the acquisition of Igeneon AG in March 2005 Aphton acquired additional late-stage products, IGN IGN Ignored (Status) IGN Institut Geographique National IGN Ignition IGN Instituto Geografico Nacional (Spain) IGN Imagine Games Network IGN In-Game Name (gaming) 101, a cancer vaccine designed to induce an immune response immune response n. An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes. against EpCAM positive tumor cells, and IGN311, a fully humanized antibody humanized antibody Molecular medicine A recombinant DNA product which ↓ non-human monoclonal antibody immunogenicity, by transferring the hypervariable genes of rodent antibodies–which encode peptide segments capable of recognizing the desired epitope, against the Lewis Y antigen. Aphton is currently seeking partners that will support the further development of Insegia (G17DT immunogen), its immunogen targeting the hormone gastrin. Aphton has strategic alliances with sanofi-aventis for the development and commercialization of Insegia related to cancers of the gastrointestinal system and other cancers in North America and Europe; Daiichi Pure Chemicals for the development, manufacturing and commercialization of gastrin-related diagnostic kits; and Xoma for treating gastrointestinal and other gastrin-sensitive cancers using anti-gastrin monoclonal and other antibodies. For more information about Aphton or its programs please visit Aphton's website at http://www.aphton.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion